A
Antonio Craxì
Researcher at University of Palermo
Publications - 699
Citations - 44773
Antonio Craxì is an academic researcher from University of Palermo. The author has contributed to research in topics: Hepatitis C & Cirrhosis. The author has an hindex of 86, co-authored 659 publications receiving 39463 citations. Previous affiliations of Antonio Craxì include University of Pavia & University of Paris-Sud.
Papers
More filters
Journal ArticleDOI
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma†
Calogero Cammà,Giuseppe Cabibbo,Salvatore Petta,Marco Enea,Massimo Iavarone,Antonio Grieco,Antonio Gasbarrini,Erica Villa,Claudio Zavaglia,Raffaele Bruno,Massimo Colombo,Antonio Craxì +11 more
TL;DR: In daily practice dose‐adjusted, but not full‐dose, sorafenib is a cost‐effective treatment compared to BSC in intermediate and advanced HCC.
Journal ArticleDOI
IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease
Salvatore Petta,Stefania Grimaudo,Calogero Cammà,Daniela Cabibi,V. Di Marco,G. Licata,Rosaria Maria Pipitone,Antonio Craxì +7 more
TL;DR: In NAFLD patients, IL28B rs12979860 CC genotype, together with PNPLA3 rs738409 GG, is associated with the severity of liver damage.
Journal Article
Epidemiology, risk factors and surveillance of hepatocellular carcinoma
Giuseppe Cabibbo,Antonio Craxì +1 more
TL;DR: Although the optimal methods of screening and the cost-effectiveness of surveillance for HCC remain to be established, systematic screening still offers the best hope for early diagnosis, treatment eligibility, and improved survival.
Journal ArticleDOI
Long-term course of interferon-treated chronic hepatitis C
Calogero Cammà,Vito Di Marco,Oreste Lo Iacono,Piero Luigi Almasio,Marco Giunta,Patrizia Fuschi,Alessandra Vaccaro,Carmelo Fabiano,S. Magrin,Rosa Di Stefano,Celestino Bonura,Luigi Pagliaro,Antonio Craxì +12 more
TL;DR: Hepatitis C virus is probably eradicated and progression of liver disease is prevented in most patients who remain HCV RNA negative with normal transaminases for more than 1 year after stopping treatment.
Journal ArticleDOI
Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection
Salvatore Petta,Calogero Cammà,Vito Di Marco,Fabio Salvatore Macaluso,Marcello Maida,Giuseppe Pizzolanti,Beatrice Belmonte,Daniela Cabibi,Rosa Di Stefano,Donatella Ferraro,Carla Guarnotta,G. Venezia,Antonio Craxì +12 more
TL;DR: The prevalence and the factors related to steatosis and IR in CHB patients, compared with CHC subjects, are assessed and the potential association between these features and fibrosis severity is evaluated.